Whalesbook
Key Decisions Announced
iSERA Lifesciences Limited's board met on April 21, 2026, to approve several key strategic and financial moves.
The company is set to acquire iSERA Biological Limited for ₹78 crore through a 1:1 share swap, aiming to make it a wholly-owned subsidiary.
To support this expansion, the authorized share capital was significantly increased from ₹11 crore to ₹25 crore, creating an additional 1.40 crore equity shares.
The board also boosted the company's investment, loan, or guarantee limit to ₹1,000 crore. Additionally, new Memorandum and Articles of Association were approved to align with current regulations.
Strategic Rationale
This acquisition is a decisive step in iSERA Lifesciences' strategic shift towards the pharmaceutical and life sciences sector, aiming to strengthen its market position.
The integration of iSERA Biological's operations is expected to create value for shareholders through combined efforts.
Company Transformation
iSERA Lifesciences previously operated as Covidh Technologies Limited, focusing on IT and software services.
In February 2026, Covidh Technologies signed a Letter of Intent to acquire iSERA Biological, which specializes in biopharmaceuticals and life sciences products.
The company officially changed its name to iSERA Lifesciences Limited in April 2026, following board and shareholder approvals, and appointed new directors to guide its transition into the life sciences sector.
Immediate Impacts
- iSERA Biological will become a wholly-owned subsidiary once the deal is finalized.
- The authorized share capital will rise to ₹25 crore, signaling readiness for future growth or financing.
- The increased ₹1,000 crore limit for investments and loans provides substantial financial flexibility.
- The company's strategic focus officially shifts from IT to the pharmaceutical and life sciences industry.
Potential Hurdles
- Approvals Needed: Both the acquisition and the share issuance require final approval from shareholders and regulatory bodies.
- Related Party Deal: The share swap is a related party transaction, though it has been certified as an arm's length deal by registered valuers.
- Historical Performance: iSERA Lifesciences, formerly an IT firm, has faced declining revenues and unprofitability. The current acquisition aims to establish a new growth path.
Competitive Landscape
iSERA Lifesciences enters the life sciences market alongside established players such as Zydus Lifesciences, Ajanta Pharma, and Laurus Labs in India.
These peers have diverse operations, from global distribution (Zydus Lifesciences) to specialized therapeutic areas (Ajanta Pharma) and API/biotechnology (Laurus Labs).
Financial Context
- iSERA Biological reported a turnover of ₹18.36 crore for FY 2024-25.
- The company's authorized share capital will rise to ₹25 crore from ₹11 crore.
- The investment and loan limit has been increased to ₹1,000 crore.
Next Steps
- Shareholders will vote on the acquisition and capital increase via postal ballot or remote e-voting.
- The company awaits In-Principle Approval from BSE Limited for the share capital increase.
- Other necessary regulatory approvals for the transaction are pending.
- Focus will be on completing the iSERA Biological acquisition and integrating its operations.
- Future financial performance and execution of its life sciences strategy will be closely watched.